Mycoplasma Mastitis

Mycoplasma mastitis represents one of the most challenging and economically devastating udder infections affecting dairy cattle, caused by species of Mycoplasma organisms that lack cell walls and resist conventional antimicrobial therapy. The condition differs fundamentally from other forms of mastitis in its resistance to treatment, tendency to spread rapidly through herds, and ability to affect multiple quarters simultaneously in infected animals. Understanding mycoplasma mastitis requires recognition of its unique characteristics including horizontal transmission during milking, persistence in carrier animals, and association with other systemic disease manifestations.

Mycoplasma mastitis occurs worldwide in dairy cattle populations, with Mycoplasma bovis representing the most common and pathogenic species, though Mycoplasma californicum, Mycoplasma bovigenitalium, and other species also cause udder infections. Prevalence varies considerably based on herd biosecurity practices, with closed herds maintaining low or zero infection rates while herds that purchase cattle without adequate screening face significant introduction risk. Surveys indicate that 5 to 10 percent of dairy herds may harbor mycoplasma infections, though within infected herds, prevalence can reach 10 to 30 percent of animals during outbreak situations. The condition affects both conventional and organic dairy operations.

The economic and welfare impact of mycoplasma mastitis is severe due to the untreatable nature of infections and the rapid spread that can occur before detection. Affected quarters typically become non-functional, and cows with multiple infected quarters usually require culling. Milk production losses in clinically affected animals are substantial, often exceeding 40 to 60 percent reduction. Treatment costs, while typically futile for cure, may be incurred before diagnosis is established. Culling losses accumulate rapidly during outbreaks. Associated conditions including arthritis, pneumonia, and otitis in calves from infected dams compound economic impacts. Welfare concerns include chronic pain, debilitation, and systemic illness in affected animals.

The lack of effective treatment for mycoplasma mastitis makes prevention and early detection critically important for dairy operations. Control programs rely on identification and removal of infected animals to eliminate pathogen reservoirs. Biosecurity practices preventing introduction through purchased cattle represent the most effective protection for negative herds. Regular bulk tank and individual cow screening allows early detection before widespread transmission occurs. Operations that maintain strict biosecurity and monitoring programs successfully avoid or control mycoplasma infections, while those with gaps in these programs face ongoing challenges.

The primary cause of mycoplasma mastitis is infection with Mycoplasma species, most commonly Mycoplasma bovis in dairy cattle. These organisms are unique among bacteria in lacking cell walls, which makes them inherently resistant to beta-lactam antibiotics and other antimicrobials targeting cell wall synthesis. Mycoplasma bovis is highly adapted to cattle and survives well in the dairy environment, persisting in infected animals as chronic carriers. Transmission occurs primarily during milking through contaminated equipment, hands, towels, or milking unit liners that contact infected quarters before moving to uninfected animals.

Genetic and breed predispositions for mycoplasma mastitis susceptibility have not been clearly established, as the condition primarily reflects exposure risk rather than inherent susceptibility differences. All dairy cattle breeds appear susceptible when exposed to adequate bacterial challenge. However, factors affecting general immune competence may influence whether exposed animals develop clinical disease or become subclinical carriers. High-producing cows may face elevated risk due to stress-related immunosuppression. Animals with compromised immunity from concurrent disease or metabolic stress may be more likely to develop clinical manifestations following exposure.

Environmental and management factors critically influence mycoplasma mastitis risk through their effects on pathogen introduction and transmission. The single most important risk factor is the purchase of cattle from external sources without adequate screening. Mycoplasma-positive cattle introduced to naive herds initiate outbreaks that spread through the milking process. Milking equipment, particularly non-replaced liners and inadequately sanitized units, can harbor organisms between cows. Sharing equipment between operations or at shows provides transmission opportunities. Large herd size and high cattle turnover increase exposure probability.

Risk factors for mycoplasma mastitis at the individual animal level include recent transportation stress, concurrent respiratory disease, and reproductive tract infections. Calves born to infected dams may acquire Mycoplasma bovis from contaminated colostrum or milk, developing respiratory disease, arthritis, or otitis that serves as a reservoir for later mastitis development. Cows recovering from mycoplasma respiratory infections may develop mastitis when organisms colonize the udder. Stress from heat, crowding, or management changes may trigger clinical disease in subclinically infected carriers.

The pathophysiology of mycoplasma mastitis involves organism colonization of the mammary gland with subsequent chronic inflammatory response. Unlike other mastitis pathogens, mycoplasma organisms can spread hematogenously from respiratory or reproductive tract infections to establish udder infection. Within the mammary gland, organisms persist intracellularly and in biofilms protected from immune clearance. The host immune response causes tissue damage without eliminating infection, resulting in progressive loss of functional secretory tissue. Multiple quarter involvement, often sequential spread through all four quarters, is characteristic of mycoplasma infections.

Early warning signs of mycoplasma mastitis may be initially subtle but progress more rapidly than many other mastitis types. Affected cows may show mild reduction in milk production from one or more quarters before obvious clinical signs develop. Milk from infected quarters may appear slightly altered with fine sand-like sediment distinguishing it from the chunky clots typical of streptococcal or staphylococcal mastitis. Some cows develop slight fever or malaise that precedes obvious udder changes. California Mastitis Test reactions may be weakly positive initially, though reactions typically intensify as infection progresses.

Common symptoms in dairy cattle with mycoplasma mastitis include rapidly progressive involvement of multiple quarters. Unlike most other mastitis pathogens that typically affect single quarters, mycoplasma infections characteristically spread to involve multiple or all quarters in affected animals. The classic presentation involves sequential quarter involvement over days to weeks. Milk production drops dramatically, often by 50 percent or more from baseline. Milk appearance becomes watery or serum-like, sometimes described as resembling dishwater, with the characteristic fine sandy sediment. Fever may be present but is often mild or absent despite severe quarter involvement.

Behavioral changes in cows with mycoplasma mastitis reflect systemic illness and udder discomfort. Affected animals often separate from the herd and spend more time lying down. Appetite decreases progressively as the condition worsens. Cows may resist milking due to udder pain and demonstrate behavioral signs of discomfort including shifting weight, kicking at the abdomen, and frequent position changes. Depression becomes more pronounced as multiple quarters become involved. Some animals develop concurrent clinical signs from other body systems infected by mycoplasma.

Physical signs associated with mycoplasma mastitis include moderate to severe udder swelling that may progress rapidly. Affected quarters feel firm and edematous, sometimes with palpable nodules representing areas of tissue consolidation. Heat and pain are present but may be less intense than with acute coliform mastitis despite extensive tissue damage. Teat edema occurs in some cases. Lymph node enlargement may be palpable. Concurrent arthritis presents as joint swelling and lameness, most commonly affecting the tarsal and carpal joints. Respiratory signs from concurrent mycoplasma pneumonia may be present.

Symptom progression in mycoplasma mastitis typically involves inexorable spread to additional quarters despite treatment attempts. Initial single-quarter involvement commonly extends to adjacent quarters within days, with all four quarters potentially affected within one to three weeks. Production from affected quarters continues to decline, and milk quality deteriorates. Chronic cases develop permanent udder atrophy as functional tissue is replaced by fibrosis. Some cows develop systemic illness with weight loss, chronic low-grade fever, and general debilitation. Animals that develop concurrent arthritis may become increasingly lame.

Emergency symptoms requiring immediate attention include rapid decline in multiple quarters suggesting outbreak initiation. Any cow with atypical mastitis affecting multiple quarters should be immediately isolated and tested for mycoplasma. Severe systemic illness with high fever, recumbency, or toxemia requires supportive care regardless of causative agent. Animals with concurrent severe respiratory distress or marked lameness need comprehensive evaluation. Recognition of potential mycoplasma involvement allows implementation of containment measures to prevent herd-wide spread.

Clinical examination for suspected mycoplasma mastitis focuses on identifying the characteristic multi-quarter involvement pattern. Systematic evaluation of each quarter including visual inspection, palpation, and milk evaluation helps characterize the extent of involvement. Documentation of which quarters are affected and the chronology of involvement supports mycoplasma suspicion. Physical examination should include evaluation for concurrent joint swelling, respiratory abnormalities, or reproductive tract involvement that may indicate systemic mycoplasma infection. Comparison of affected animals to herdmates may reveal clustering suggesting an outbreak.

Diagnostic testing for mycoplasma mastitis requires specialized culture techniques because these organisms will not grow on standard aerobic culture media. Samples must be submitted to laboratories with mycoplasma culture capability using appropriate transport media maintaining organism viability. Culture takes seven to fourteen days due to the slow growth rate of mycoplasma organisms. Polymerase chain reaction testing provides rapid detection within one to two days and offers high sensitivity for identifying mycoplasma genetic material in milk samples. Bulk tank PCR screening allows cost-effective herd monitoring, with positive results triggering individual cow testing to identify infected animals.

Differential diagnosis for mycoplasma mastitis includes other causes of severe or unusual mastitis presentations. Staphylococcus aureus occasionally causes multiple quarter involvement, though less rapidly progressive than mycoplasma. Serratia and Pseudomonas mastitis can be treatment-resistant and severe. Nocardia mastitis presents with chronic progressive disease. Prototheca mastitis causes treatment-resistant infections with watery milk. Standard culture identifying these other pathogens helps differentiate them from mycoplasma. The sandy sediment and rapid multi-quarter spread pattern strongly suggest mycoplasma, but laboratory confirmation is essential.

Herd-level diagnostics for mycoplasma monitoring include regular bulk tank testing as the cornerstone of surveillance programs. Monthly bulk tank PCR testing provides early warning of herd infection status. Individual cow composite or quarter sampling identifies specific infected animals for management decisions. Screening of all purchased cattle before herd integration prevents introduction of positive animals. String samples testing groups of ten to twenty cows allow efficient identification of positive strings for targeted individual testing. Culture of calves with respiratory disease, arthritis, or otitis may reveal mycoplasma circulation in the heifer population.

Emergency treatment for severe clinical cases of mycoplasma mastitis focuses on supportive care rather than curative antimicrobial therapy. Affected cows may benefit from anti-inflammatory medications to reduce fever and discomfort. Fluid therapy supports hydration in animals with reduced appetite. Frequent milking helps remove accumulated secretions from affected quarters. Calcium supplementation may be needed for periparturient cows. The critical immediate priority is isolation of suspected cases to prevent transmission to other animals while awaiting diagnostic confirmation.

Medical management options for mycoplasma mastitis are severely limited due to the inherent resistance of mycoplasma organisms to most antimicrobials. While some antibiotics including tetracyclines, macrolides, and fluoroquinolones demonstrate in vitro activity against mycoplasma, clinical cure of mastitis is rarely achieved. Intramammary antibiotic therapy is generally ineffective because organisms persist within cells and biofilms beyond drug penetration. Systemic treatment may reduce organism shedding temporarily but does not eliminate infection. Treatment attempts typically waste resources while allowing continued transmission if animals are not properly isolated.

Surgical intervention has no role in mycoplasma mastitis management. The diffuse nature of infection throughout affected quarters precludes localized surgical approaches. Dry period therapy does not cure mycoplasma infections, as organisms persist and reactivate with lactation. Quarter infusions of various substances have been attempted without consistent success. The absence of effective curative treatments underscores the critical importance of prevention and removal of infected animals.

Supportive care for cows with mycoplasma mastitis includes provision of clean, dry housing separated from the milking herd. Comfortable bedding and easy access to feed and water support animals that may be debilitated. Pain management through approved anti-inflammatory medications maintains welfare while culling decisions are made. Milking of affected quarters prevents accumulation of secretions and associated discomfort. Animals awaiting culling should be maintained humanely but with strict biosecurity to prevent transmission.

Herd treatment protocols for mycoplasma focus on identification and removal of positive animals rather than treatment of individuals. Test-and-cull programs screen the entire milking herd to identify all infected animals. Positive cows should be culled as promptly as practical, either immediately or after a fattening period in isolated facilities. Bulk tank monitoring following removal confirms success of eradication efforts. Continued surveillance detects any recurrence from animals that escaped initial detection. Dry cows should be tested before calving to prevent introduction of undetected carriers into the milking herd.

Treatment decisions for mycoplasma mastitis must prioritize herd health over individual animal treatment. The untreatable nature of infection and high transmission risk make culling the appropriate management decision in nearly all cases. Economic analysis consistently supports culling over retention attempts due to production losses, transmission risk, and treatment costs without benefit. Salvage slaughter value should be captured if animals are marketable. Animals too debilitated for slaughter may require euthanasia. Welfare considerations support timely culling decisions rather than prolonged supportive care without hope of cure.

Recovery from mycoplasma mastitis is not expected for affected quarters, and individual animal prognosis is poor. Infected quarters do not return to normal function, and the organisms typically persist indefinitely in affected tissue. Apparent clinical improvement may occur with supportive care, but this represents reduction in inflammation rather than elimination of infection. Production from affected quarters remains depressed, and subclinical shedding continues to pose transmission risk. The chronic nature of mycoplasma infection means that apparent recovery should not be mistaken for cure.

Post-exposure monitoring for herds that have experienced mycoplasma introduction includes intensive surveillance to identify any additional cases. Weekly bulk tank PCR testing for the first several months following eradication efforts detects recurrence. Individual cow testing before calving identifies positive dry cows before they enter the milking herd. Clinical monitoring for new cases of multi-quarter mastitis prompts immediate testing and isolation. Maintaining heightened awareness for at least a full year following outbreak resolution allows detection of late-appearing cases.

Prognosis factors for mycoplasma mastitis at the individual level are uniformly unfavorable. Single-quarter involvement typically progresses to multiple quarters. Bacteriological cure is not achieved with available treatments. Production never returns to previous levels in affected quarters. Chronic subclinical infection persists indefinitely with continued shedding risk. Animals developing concurrent arthritis face compounded welfare concerns. The combination of incurable infection, welfare implications, and transmission risk makes culling the appropriate outcome.

Return to production is not applicable for individual cows with mycoplasma mastitis, but herd recovery from outbreaks is achievable through systematic control programs. Following removal of all positive animals, bulk tank and individual cow testing should confirm negative status. Return to normal production levels occurs as culled animals are replaced with healthy heifers or purchases from tested-negative sources. Restoration of quality premiums follows return to low bulk tank somatic cell counts. Recovery of herd reproductive efficiency may take longer if concurrent reproductive mycoplasma involvement occurred.

Vaccination for mycoplasma mastitis is not currently available or effective. Research into mycoplasma vaccines has not produced products demonstrating reliable protection against mastitis or other mycoplasma diseases. The complex biology of mycoplasma organisms, including their ability to vary surface antigens, has frustrated vaccine development efforts. Some bacterin products marketed for respiratory mycoplasma disease are available, but these do not reliably prevent mastitis. Vaccine development remains an active research area, but prevention currently depends entirely on biosecurity and surveillance approaches.

Biosecurity measures represent the cornerstone of mycoplasma mastitis prevention for dairy operations. The most critical practice is avoiding introduction of infected cattle by purchasing only from herds with documented mycoplasma-negative status or by testing all purchased cattle before integration. Quarantine of new arrivals for three to four weeks with testing during that period identifies positive animals before herd contact. Avoiding cattle purchases from auctions, dealers, or other high-risk sources eliminates the most common introduction pathway. Show cattle returning to the farm should be tested before reintegration.

Nutritional prevention strategies for mycoplasma mastitis focus on maintaining optimal immune function rather than specific mycoplasma prevention. Adequate selenium, vitamin E, copper, and zinc support immune competence that may help resist infection establishment following exposure. Avoiding negative energy balance during transition reduces immunosuppression during this vulnerable period. Maintaining excellent body condition and avoiding metabolic stress keeps defenses optimal. Colostrum quality optimization supports calf immunity against mycoplasma and other pathogens.

Management practices preventing mycoplasma transmission within herds include strict milking hygiene when positive animals are identified. Infected cows should be milked last or with dedicated equipment until culled. Single-service towels prevent transfer between animals. Teat dipping with effective germicides reduces organism survival on teat skin. Milking equipment maintenance ensures proper function without teat damage that might increase susceptibility. Separate equipment for calves from infected dams prevents exposure through feeding utensils.

Quarantine and testing protocols form the operational framework for mycoplasma control. Bulk tank PCR testing monthly establishes baseline herd status and provides ongoing surveillance. Individual cow testing follows any positive bulk tank result to identify affected animals. All purchased cattle undergo testing during quarantine with negative results required before herd integration. Fresh cows may be tested before entering the milking herd in high-risk situations. Documentation of testing results supports verification of herd status for sales or regulatory purposes.

Daily management of mycoplasma-positive herds during eradication efforts requires intensive monitoring and strict biosecurity protocols. Positive cows must be clearly identified and milked last or with dedicated equipment. Daily observation identifies new clinical cases requiring immediate testing and isolation. Milk from positive cows must be discarded and never fed to calves. Personnel handling positive animals should not contact susceptible animals without sanitation measures. Record keeping tracks positive animal status and scheduled removal dates.

Housing for mycoplasma-positive animals pending culling should be separate from the main herd whenever possible. Dedicated facilities prevent contact transmission to susceptible animals. If separate housing is unavailable, positive animals may be grouped together at one end of facilities with physical separation from negative animals. Equipment including waterers, feed bunks, and bedding materials should not be shared between positive and negative groups. Manure handling should prevent contamination of negative animal areas.

Herd health programs for mycoplasma prevention in negative herds emphasize ongoing surveillance and biosecurity maintenance. Monthly bulk tank testing confirms continued negative status. Clear protocols define cattle sourcing, quarantine, and testing requirements. New employee training includes mycoplasma awareness and milking hygiene importance. Veterinary consultation reviews protocols annually and following any new cattle additions. Documentation systems maintain testing records and support response if positive results occur.

Record keeping for mycoplasma management includes bulk tank testing results, individual animal test results, identification of positive animals, and culling dates. Testing of purchased cattle during quarantine should be documented with results archived. Clinical mastitis records noting multi-quarter involvement trigger mycoplasma testing consideration. Bulk tank somatic cell count trends may suggest emerging problems warranting investigation. Complete records support regulatory compliance if required and facilitate outbreak response.

Economic considerations for mycoplasma management influence prevention investment levels. The catastrophic costs of outbreaks, including mass culling, production losses, and milk quality impacts, justify substantial prevention spending. Testing costs for bulk tank monitoring represent inexpensive insurance against undetected introduction. Quarantine facility investment pays dividends in biosecurity protection. Premium pricing for mycoplasma-tested purchases reflects true risk reduction value. Cost-benefit analysis strongly supports prevention over outbreak response, as control costs typically exceed prevention investments by large multiples.

High-risk situations for mycoplasma mastitis relate more to management practices than breed characteristics. All dairy cattle breeds appear susceptible when exposed to adequate organism challenge. Large commercial operations with frequent cattle purchases face higher introduction risk than closed herds. Herds with rapid expansion programs bringing in cattle from multiple sources have elevated exposure probability. Operations participating in shows, fairs, or cattle leasing programs face increased contact opportunities. Dairy operations adjacent to beef cattle with endemic mycoplasma respiratory disease may face environmental exposure risk.

Production type considerations influence mycoplasma mastitis risk profiles. High-producing dairy cows may be more susceptible due to metabolic stress affecting immunity. Organic operations face particular challenges if mycoplasma introduction occurs because antimicrobial treatment is not permitted and would be ineffective regardless. Seasonal dairy operations may face concentrated calving periods with elevated fresh cow susceptibility. Robotic milking systems may face challenges ensuring proper hygiene protocols when positive animals are identified. Transition cow management quality significantly affects susceptibility during the high-risk early lactation period.

Genetic selection for mycoplasma mastitis resistance is not currently possible because no genetic markers or reliable resistance traits have been identified. General immune function traits may provide some benefit through enhanced resistance to initial infection establishment. Selection for udder health using somatic cell score and clinical mastitis traits improves overall mastitis resistance. Maintaining genetic diversity avoids potential susceptibility concentration. Research into mycoplasma resistance genetics may eventually identify selectable traits, but current prevention depends entirely on management rather than genetics.

Commonly co-occurring conditions with mycoplasma mastitis reflect the systemic nature of Mycoplasma bovis infection. Mycoplasma arthritis presents as joint swelling and lameness, most commonly affecting tarsal and carpal joints in the same animals with mastitis. Respiratory disease ranging from mild pneumonia to severe consolidating pneumonia affects calves and adults. Otitis media in calves causes head tilt, ear droop, and circling behavior and may be the first indication of mycoplasma presence on a farm. Reproductive tract infections including granular vulvovaginitis and salpingitis affect breeding animals. Eye infections presenting as conjunctivitis or keratitis occur in some outbreaks.

Conditions with similar symptoms requiring differentiation from mycoplasma mastitis include other causes of treatment-resistant or multi-quarter mastitis. Staphylococcus aureus occasionally causes progressive multi-quarter involvement, though typically more slowly than mycoplasma. Pseudomonas mastitis resists most antibiotics and can be severe. Prototheca mastitis produces watery secretions and resists treatment. Nocardia mastitis causes chronic progressive disease with treatment failure. Fungal mastitis from various organisms produces unusual clinical presentations. Laboratory testing differentiates these conditions because treatment and management implications differ.

Complications and sequelae of mycoplasma mastitis include permanent loss of affected quarter function. Progressive involvement of additional quarters leads to total udder loss in many cases. Systemic spread causing arthritis, respiratory disease, or other manifestations compounds animal suffering and economic loss. Calves from infected dams may develop mycoplasma disease affecting multiple body systems. Transmission to herdmates occurs through milking equipment contamination. Economic consequences include production losses, culling costs, replacement expenses, and milk quality impacts affecting the entire operation.